CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine

[1] Mitsikostas DD(2017)Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies Curr Opin Neurol 30 272-280

[2] Reuter U(2015)Therapeutic antibodies against CGRP or its receptor Br J Clin Pharmacol 79 886-895

[3] Bigal ME(2011)Calcitonin gene-related peptide (CGRP) and its role in hypertension Neuropeptides 45 93-104

[4] Walter S(2015)CGRP as a neuropeptide in migraine: lessons from mice Br J Clin Pharmacol 80 403-414

[5] Rapoport AM(2015)Adherence to oral migraine-preventive medications among patients with chronic migraine Cephalalgia 35 478-488

[6] Smillie SJ(2007)Patients’ preference for migraine preventive therapy Headache 47 540-545

[7] Brain SD(2009)Rejection and acceptance of possible side effects of migraine prophylactic drugs Headache 49 1022-1027

[8] Russo AF(2016)A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability Headache 56 1280-1289

[9] Hepp Z(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden Of Migraine Study (IBMS-II) Headache 53 644-655

[10] Dodick DW(2015)Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study Lancet Neurol 14 1091-1100

[1] Mitsikostas DD(2017)Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies Curr Opin Neurol 30 272-280

[2] Reuter U(2015)Therapeutic antibodies against CGRP or its receptor Br J Clin Pharmacol 79 886-895

[3] Bigal ME(2011)Calcitonin gene-related peptide (CGRP) and its role in hypertension Neuropeptides 45 93-104

[4] Walter S(2015)CGRP as a neuropeptide in migraine: lessons from mice Br J Clin Pharmacol 80 403-414

[5] Rapoport AM(2015)Adherence to oral migraine-preventive medications among patients with chronic migraine Cephalalgia 35 478-488

[6] Smillie SJ(2007)Patients’ preference for migraine preventive therapy Headache 47 540-545

[7] Brain SD(2009)Rejection and acceptance of possible side effects of migraine prophylactic drugs Headache 49 1022-1027

[8] Russo AF(2016)A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability Headache 56 1280-1289

[9] Hepp Z(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden Of Migraine Study (IBMS-II) Headache 53 644-655

[10] Dodick DW(2015)Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study Lancet Neurol 14 1091-1100